Oncology

Latest News

Estrogen | Image credit: Debalina - stock.adobe.com
Estrogen Therapy May Increase Risk of 3 Skin Cancers

March 20th 2025

Researchers of a Swedish study advise physicians to consult with their patients about these risks and take extra precautions, but did not recommend discontinuation of any of the drugs studied.

Karen Winkfield, MD, PhD
Expanding Access to Clinical Trials Through Community Partnerships

March 19th 2025

Texas Oncology logo | Image: Texas Oncology
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot

March 18th 2025

Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year
Cancer Labels on Alcohol? Ireland, Where Pubs Still Rule, Will Have Them by Next Year

March 17th 2025

Doctor screening patient for skin cancer | Image credit: Seventyfour – stock.adobe.com
Patients Prefer AI in Skin Cancer Screening as an Assistive Tool, Not a Replacement

March 14th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
August 20th 2013

Sequester Forcing Chemo Treatments into Hospitals Costing Taxpayers More in the End

Stanton R. Mehr
Site Logo
August 19th 2013

Drug Shortages Persist in Wake of Surveys

Beth Fand Incollingo Mary K. Caffrey
Site Logo
August 19th 2013

Managed Care Experts and Oncologists Discuss Reimbursement, Access Issues Associated with Expensive New Cancer Therapies

Expert panel convened by the American Journal of Managed Care provides insight into the challenges faced by clinicians and payers when administering cutting-edge cancer medications.
Site Logo
August 19th 2013

Changing the Cancer Landscape

Since the rise of genetics and advanced molecular biology, cancer research is a field that has become almost as obsessed with understanding aberrant metabolism as it is with devising therapies.
Michael Kolodziej Says Provider-Payer Connections Key in Quality, Cost-Effective Cancer Care
August 15th 2013

Michael Kolodziej Says Provider-Payer Connections Key in Quality, Cost-Effective Cancer Care

In order to deliver quality and cost-effective cancer care, Michael Kolodziej, MD, Aetna's national medical director for oncology strategies, says that providers need to get better connected with payers.
Site Logo
August 12th 2013

Cost of Care for Malignant and Benign Renal Masses

Aviva G. Asnis-Alibozek, PA-C Michael J. Fine, MD Paul Russo, MD Trent McLaughlin, BSc(Pharm), PhD Eileen M. Farrelly, MPH Norman LaFrance, MD William Lowrance, MD, MPH
Methods for better identifying malignant versus benign disease before nephrectomy could provide significant benefits to patients and payers.
Site Logo
August 8th 2013

Health Reform Will Cost Cancer Patients

Katie Sullivan
In an effort to offset cost increases associated with the Affordable Care Act (ACA), the Obama administration intends to expand hospitals' access of the 340B discount drug plan. While the expansion may sound promising to some, many others worry that the program will threaten the quality of care, as increased participation risks higher potential for abuse. Even worse, the 340B program will likely rise the cost of cancer care.
Site Logo
August 8th 2013

Lung Cancer Pattern Predicts Recurrence

For patients with early-stage lung adenocarcinomas, the histological pattern of the tumor predicts the risk of recurrence and might help guide surgical decisions.
Site Logo
August 1st 2013

Narrowing Physician Access Puts Pharma in a Bind

Katie Sullivan
Oncologists have a reputation to maintain - and according to the latest report from ZS Associates, when it comes to fortifying against pharmaceutical sales representatives, the specialty remains characteristically hardboiled for the second year in a row.
Site Logo
July 30th 2013

Panel Backs Lung Cancer Screening for Smokers

For the first time, government advisers are recommending screening for lung cancer, saying certain current and former heavy smokers should get annual scans to cut their chances of dying of the disease.
Segment 7- Healthcare System Challenges
July 29th 2013

Segment 7- Healthcare System Challenges

Panelists agreed that the cost of the new agents discussed to treat melanoma will be a challenge, just as the cost of healthcare as a whole in the United States is a major challenge.
Segment 6- Competition in the Marketplace
July 29th 2013

Segment 6- Competition in the Marketplace

Dr Fendrick asked panelists what they think about the idea of centers of excellence for specific cancers and an evidence-based steerage.
Segment 5- New Payment Models in Oncology
July 29th 2013

Segment 5- New Payment Models in Oncology

It's very, very complex to try to envision how you would come up with a single payment for an episode and not have a thousand different types of episodes in order to capture the heterogeneity of these diseases and the cost, said Dr Malin when asked to discuss the bundled payment method in oncology.
Segment 4- Nonadherence Caused by a Lack of Access
July 29th 2013

Segment 4- Nonadherence Caused by a Lack of Access

In this portion of the panel discussion, Dr Fendrick asked the panel whether or not they have noticed cost-related lack of access or nonadherence with the new agents being discussed.
Segment 3- How Payers Will Access the Value of New Agents
July 29th 2013

Segment 3- How Payers Will Access the Value of New Agents

Dr Weber said that despite all of the newer agents in development, the NCCN still offers comprehensive guidelines for the treatment of melanoma.
Segment 2- Emerging Immunotherapies for the Treatment of Metastatic Melanoma
July 29th 2013

Segment 2- Emerging Immunotherapies for the Treatment of Metastatic Melanoma

Dr Ribas opened this segment by discussing the new immunotherapy agents used in the treatment of metastatic melanoma. Specifically, he discussed the agents vemurafenib (Zelboraf), dabrafenib (Taflinar), and trametinib (Mekinist).
Segment 1- Introduction and Therapeutic Overview
July 29th 2013

Segment 1- Introduction and Therapeutic Overview

Panel moderator and AJMC co-editor-in-chief Dr Mark Fendrick introduced panelists Jennifer Malin, MD, PhD, manager and medical director of oncology, WellPoint; Jeffrey Weber, MD, PhD, senior member, H. Lee Moffitt Cancer Center Director, Donald A. Adam Comprehensive Melanoma Research Center; and Antoni Ribas, MD, PhD, Jonsson Comprehensive Cancer Center, UCLA.
Site Logo
July 22nd 2013

More Evidence Not All Prostate Cancers Need Treatment

In a study of older men who had died from causes other than prostate cancer, almost half were found to have prostate tumors. And up to half of those tumors detected on autopsy would have qualified for treatment had doctors known about them while the men lived, though none had been the cause of death.
Site Logo
July 19th 2013

Lung Cancer Screening Most Useful in High-risk People

Using low-dose CT scans to screen high-risk patients for lung tumors is far more effective at preventing lung cancer deaths than scanning those at low risk, according to a new analysis of over 53,000 volunteers.
Segment 5: The Role of Companion Diagnostics/The Effect of New Payment Models
July 18th 2013

Segment 5: The Role of Companion Diagnostics/The Effect of New Payment Models

In the final segment, panelists examine the use of companion diagnostics to determine proper patient utilization. Dr. Chernew asks if the required diagnostic testing is being appropriately used and if they are being covered by payers.
Segment 4: Reimbursement and Clinical Pathways
July 18th 2013

Segment 4: Reimbursement and Clinical Pathways

This segment of the panel discussion takes a closer look at the episode of cost for a patient going to a hospital versus a private office setting. Panelists agree that the cost of hospital care is not that much greater than in the office.
Segment 3: How Payers are assessing the Value of New Agents
July 18th 2013

Segment 3: How Payers are assessing the Value of New Agents

Dr. Chernew asks the panelists how payers address the value of these costly combination therapies when there are less expensive options available. Dr. Newcomer says that the drugs being discussed are, in fact, having a significant clinical effect.
Segment 2: Overview of Results from EMILIA and MARIANNE Trials
July 18th 2013

Segment 2: Overview of Results from EMILIA and MARIANNE Trials

In this clip, Dr. Swain and Dr. Newcomer discuss the results from the EMILIA trial. Dr. Swain notes that the survival benefit with the use of TDM-1 was five months.
Segment 1: Introduction and Patient Population
July 18th 2013

Segment 1: Introduction and Patient Population

Moderator and AJMC co-editor-in-chief, Dr. Michael Chernew delivers a brief overview of the discussion. The discussion focuses on the use of trastuzumab emtansine (Kadcyla) and pertuzumab (Perjeta). Panelists address the patient populations for the two agents and identify which are eligible to take the targeted therapy.
Site Logo
July 12th 2013

Bill Pushes Legislation to Restore Medicare Funding for Cancer Treatments

A new bill, Cancer Patient Protection Act of 2013 (HR 1416), is aiming to restore Medicare reimbursements for anti-cancer drugs and biologicals to pre-sequester levels
Site Logo
July 11th 2013

Shared Decision Making Uncommon in PSA Screening

While American Urological Association and American College of Physician guidelines suggest shared-decision making in prostate specific antigen (PSA) screen testing, most patients have not had part in discussing those decisions.
Site Logo
July 3rd 2013

Trials Begin for New Novel Immunotherapy in Melanoma

A clinical research study at Rosewell Park Cancer Institute (RPCI) will be examining a new novel immunotherapy approach to treating advanced melanoma.
Site Logo
July 2nd 2013

Access to Insurance May Be Reason for Rising Thyroid Cancer Diagnosis

Episode 17 - Conclusion: Treatment Advancements and Final Remarks
July 2nd 2013

Episode 17 - Conclusion: Treatment Advancements and Final Remarks

Episode 16 - MRI Scans and MS
July 2nd 2013

Episode 16 - MRI Scans and MS

<1
...
168169170171172173174175176
...
183>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo